Universal Beteiligungs und Servicegesellschaft mbH Lowers Stock Position in Enovis Corporation $ENOV

Universal Beteiligungs und Servicegesellschaft mbH reduced its position in Enovis Corporation (NYSE:ENOV) by 99.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 8,552 shares of the company’s stock after selling 888,425 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH’s holdings in Enovis were worth $259,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in ENOV. Capital Fund Management S.A. acquired a new position in shares of Enovis during the 2nd quarter valued at $1,682,000. Assenagon Asset Management S.A. purchased a new position in Enovis in the third quarter valued at about $4,045,000. Rhumbline Advisers lifted its stake in shares of Enovis by 32.4% during the second quarter. Rhumbline Advisers now owns 172,341 shares of the company’s stock worth $5,405,000 after purchasing an additional 42,138 shares in the last quarter. Osaic Holdings Inc. boosted its position in shares of Enovis by 56.0% in the second quarter. Osaic Holdings Inc. now owns 139,727 shares of the company’s stock worth $4,382,000 after buying an additional 50,156 shares during the period. Finally, Boston Partners grew its stake in shares of Enovis by 42.4% in the second quarter. Boston Partners now owns 1,382,724 shares of the company’s stock valued at $43,352,000 after buying an additional 411,744 shares in the last quarter. Institutional investors and hedge funds own 98.45% of the company’s stock.

Enovis Stock Down 1.8%

NYSE:ENOV opened at $21.78 on Wednesday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.16 and a current ratio of 2.22. The company has a market capitalization of $1.25 billion, a price-to-earnings ratio of -0.92 and a beta of 1.52. Enovis Corporation has a one year low of $21.00 and a one year high of $47.26. The stock has a 50-day simple moving average of $26.20 and a 200 day simple moving average of $28.77.

Enovis (NYSE:ENOV) last issued its earnings results on Thursday, November 6th. The company reported $0.75 EPS for the quarter, topping the consensus estimate of $0.67 by $0.08. The company had revenue of $548.91 million during the quarter, compared to analyst estimates of $538.61 million. Enovis had a positive return on equity of 7.79% and a negative net margin of 61.22%.The business’s revenue was up 8.7% on a year-over-year basis. During the same quarter last year, the firm earned $0.73 EPS. Enovis has set its FY 2025 guidance at 3.100-3.250 EPS. Sell-side analysts predict that Enovis Corporation will post 2.79 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently commented on ENOV. BTIG Research began coverage on Enovis in a research report on Tuesday, January 6th. They set a “buy” rating and a $41.00 price target on the stock. Wells Fargo & Company boosted their target price on shares of Enovis from $41.00 to $42.00 and gave the stock an “overweight” rating in a research report on Friday, November 7th. Canaccord Genuity Group decreased their target price on shares of Enovis from $58.00 to $50.00 and set a “buy” rating for the company in a research note on Wednesday, December 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enovis in a research note on Wednesday, October 8th. Finally, Evercore ISI reissued an “outperform” rating on shares of Enovis in a research report on Monday, January 12th. Seven analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $46.71.

Insiders Place Their Bets

In other Enovis news, insider John Kleckner acquired 2,468 shares of the company’s stock in a transaction that occurred on Tuesday, November 25th. The shares were purchased at an average price of $30.32 per share, for a total transaction of $74,829.76. Following the completion of the purchase, the insider directly owned 12,302 shares in the company, valued at $372,996.64. The trade was a 25.10% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Daniel A. Pryor sold 999 shares of the firm’s stock in a transaction dated Tuesday, December 9th. The stock was sold at an average price of $27.20, for a total transaction of $27,172.80. Additional details regarding this sale are available in the official SEC disclosure. 2.70% of the stock is currently owned by corporate insiders.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.